In contrast to the in vivo system, recIL‐22 effectively stimulated cell proliferation in in vitro settings, which is in corroboration with earlier in vitro findings on the proliferative effects of IL‐22 on breast cancer cells (Kim et al., 2014; Rui et al., 2017). Here, IL22 is linked to breast carcinoma.